LOBE SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | 0.00% |
|
+33.33% | -20.00% |
| Feb. 15 | Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023 | CI |
| 2023 | Lobe Sciences Provides Update on L-130 Clinical Program | MT |
Valuation
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 9.717 | 5.594 | 14.6 | 3.656 | 3.878 |
| Enterprise Value (EV) 1 | 9.204 | 5.724 | 7.003 | 2.723 | 3.99 |
| P/E ratio | -9.19 x | -1.53 x | -1.23 x | -0.29 x | -0.55 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 12.6 x | 6.32 x | - | - | 4.61 x |
| EV / Revenue | 11.9 x | 6.47 x | - | - | 4.75 x |
| EV / EBITDA | -3.64 x | -1.84 x | -1.14 x | -0.66 x | -1.2 x |
| EV / FCF | -119,268,553 x | -22,910,278 x | -1,761,136 x | 5,246,847 x | -4,203,548 x |
| FCF Yield | -0% | -0% | -0% | 0% | -0% |
| Price to Book | 1.59 x | 0.83 x | 1.29 x | 8.2 x | -12.4 x |
| Nbr of stocks (in thousands) | 11,169 | 13,319 | 37,439 | 38,488 | 155,136 |
| Reference price 2 | 0.8700 | 0.4200 | 0.3900 | 0.0950 | 0.0250 |
| Announcement Date | 12/24/19 | 12/21/20 | 12/24/21 | 12/22/22 | 2/15/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.5674 | 0.7738 | 0.8848 | - | - | 0.8405 |
| EBITDA 1 | -3.047 | -2.531 | -3.107 | -6.162 | -4.113 | -3.316 |
| EBIT 1 | -3.293 | -2.903 | -3.323 | -6.378 | -4.123 | -3.359 |
| Operating Margin | -580.28% | -375.1% | -375.56% | - | - | -399.67% |
| Earnings before Tax (EBT) 1 | -11.1 | -0.7544 | -3.436 | -23.84 | -12.25 | -4.502 |
| Net income 1 | -11.1 | -0.7544 | -3.436 | -9.658 | -12.25 | -4.707 |
| Net margin | -1,956.29% | -97.5% | -388.33% | - | - | -560.04% |
| EPS 2 | -2.602 | -0.0947 | -0.2738 | -0.3170 | -0.3236 | -0.0451 |
| Free Cash Flow | - | -0.0772 | -0.2498 | -3.976 | 0.519 | -0.9493 |
| FCF margin | - | -9.97% | -28.24% | - | - | -112.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/30/19 | 12/24/19 | 12/21/20 | 12/24/21 | 12/22/22 | 2/15/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.13 | - | - | 0.11 |
| Net Cash position 1 | 2.49 | 0.51 | - | 7.6 | 0.93 | - |
| Leverage (Debt/EBITDA) | - | - | -0.0418 x | - | - | -0.0338 x |
| Free Cash Flow | - | -0.08 | -0.25 | -3.98 | 0.52 | -0.95 |
| ROE (net income / shareholders' equity) | - | -15.5% | -37.6% | -195% | -209% | -3,297% |
| ROA (Net income/ Total Assets) | - | -26.3% | -21.1% | -31.8% | -37.2% | -104% |
| Assets 1 | - | 2.867 | 16.29 | 30.37 | 32.92 | 4.537 |
| Book Value Per Share 2 | 0.0600 | 0.5500 | 0.5100 | 0.3000 | 0.0100 | -0 |
| Cash Flow per Share 2 | 0.0400 | 0.0500 | 0.0100 | 0.0300 | 0.0200 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/30/19 | 12/24/19 | 12/21/20 | 12/24/21 | 12/22/22 | 2/15/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 2.41M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- LOBE Stock
- Financials Lobe Sciences Ltd.
